Impact of KRAS mutational status on outcomes in patients with pancreatic cancer (PDAC).

Volume: 39, Pages: 4142 - 4142
Published: May 28, 2021
Abstract
4142Background: KRAS mutations (m) (KRASm) are present in over 90% of pancreatic adenocarcinomas (PDAC) with a predominance of G12 substitutions. KRAS wildtype (WT) PDAC relies on alternate...
Paper Details
Title
Impact of KRAS mutational status on outcomes in patients with pancreatic cancer (PDAC).
Published Date
May 28, 2021
Volume
39
Pages
4142 - 4142
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.